LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Larimar Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.12+0.14 (+6.80%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Larimar Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Market Cap | $220.23M | $166.30M |
| Enterprise Value | $63.93M | $88.19M |
| PB Ratio | 1.73 | 2.03 |
| P/TBV Ratio | 1.73 | 2.29 |
Income (trailing twelve months)
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$178.99M | -$21.40M |
| Net Income | -$172.61M | -$22.46M |
| EBITDA | -$178.99M | -$16.91M |
Returns
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -139.6% | -53.2% |
| Return on Assets (ROA) | -109.5% | -40.9% |
| Return on Capital Employed (ROCE) | -136.5% | -38.1% |
Balance sheet
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $156.30M | $61.43M |
| Net Cash (Debt) | $156.30M | $15.35M |
| Net Cash Per Share | $1.50 | $0.66 |
| Equity (Book Value) | $127.38M | $49.09M |
| Book Value Per Share | $1.23 | $1.37 |
| Tangible Book Value | $127.38M | $23.52M |
| Working Capital | $126.51M | $76.81M |
Financial position
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.70 | 3.34 |
| Quick Ratio | 4.57 | 2.44 |
Efficiency
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.43M | -$703.34K |
| Employee Count | 71 | 74 |
Dividends and yields
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -78.4% | -23.3% |
Shares
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 103,883,000 | 58,127,000 |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 35,009,300 | 49,136,700 |
| Shares Held by Insiders | 66.3% | 11.6% |
| Shares Held by Institutions | 91.9% | 59.4% |
Scores
| Measure | Larimar Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.38 | -0.22 |
Calculated by StockData from Larimar Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.